🔎 Trials Near Me

Utama › Skleroderma › Texas

Kajian klinikal Skleroderma di Texas

12 kajian untuk Skleroderma sedang mencari peserta di lokasi di Texas.

Bandar di Texas

Teks kajian rasmi (Bahasa Inggeris)

A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  • Tekton Research, Inc - West Gate Boulevard, Austin
  • Arthritis & Rheumatology Institute - Frisco, Frisco
  • The University of Texas Health Science Center at Houston, Houston
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT07497087

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

  • UT Southwestern Simmons Cancer Center - RedBird, Dallas
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
  • UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
  • dan 2 lagi
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT03816345

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

  • GSK Investigational Site, Denison
  • GSK Investigational Site, El Paso
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Sep 2026 · NCT05878717

Platform Clinical Study for Conquering Scleroderma

  • University of Texas Houston - Division of Rheumatology and Clinical Immunogenetics, Houston
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Ogo 2026 · NCT06195072

A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

  • Nkarta Investigational Site, Dallas
  • Nkarta Investigational Site, Houston
Mengambil pesertaFasa 1/2
Umur 18 hingga 75 · Semua jantina · Dikemas kini 7 Ogo 2026 · NCT06733935

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

  • Artiva Investigational Site Arlington, Arlington
  • Artiva Investigational Site Bellaire, Bellaire
  • Artiva Investigational Site Irving, Irving
  • dan 4 lagi
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 31 Jul 2026 · NCT06991114

A Study of Microbiome Transplantation for the Treatment of Constipation and/or Significant Bloating in Patients With Systemic Sclerosis

  • The University of Texas Health Science Center at Houston, Houston
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Jul 2026 · NCT06827977

Morphea in Adults and Children (MAC) Cohort Study: A Morphea Registry and DNA Repository

  • UT Southwestern Medical Center - Department of Dermatology, Dallas
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Sehingga umur 90 · Semua jantina · Dikemas kini 12 Mei 2026 · NCT01808937

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

  • MD Anderson Cancer Center, Houston
  • The University of Texas Health Science Center at Houston, Houston
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Apr 2026 · NCT06434363

A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis

  • Galderma Investigational Site#7096, Arlington
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 31 Mac 2026 · NCT07047690

Interrogating the Pathophysiological Mechanisms of Constipation in Patients With Systemic Sclerosis

  • The University of Texas Health Science Center at Houston, Houston
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 26 Jun 2025 · NCT05989763

Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

  • aTyr Investigative Site, Dallas
  • aTyr Investigative Site, Houston
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 7 Mei 2025 · NCT05892614

Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.